Ligand Pharmaceuticals raises target price to $350 from $345
LGND•Barclays raised its target price for Ligand Pharmaceuticals to $350 from $345.
Related News
CoreWeave jumps after Q3 revenue beat, targets 2028 profitability
CRWV•
Universal Health Services target price raised to $225 from $200
UHS•
WisdomTree AUM falls to $166.85 billion in October
WT•
Zymeworks Inc.: Citigroup raises target price to $44 from $39
ZYME•
Nasdaq trade halt continues, reason not available at 03:58 a.m.
HCHL•